Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines

被引：325

作者：

Ettinger, David S. ^{[1
]}

Wood, Douglas E. ^{[2
]}

Akerley, Wallace ^{[3
]}

Bazhenova, Lyudmila A. ^{[4
]}

Borghaei, Hossein ^{[5
]}

Camidge, David Ross ^{[6
]}

Cheney, Richard T. ^{[7
]}

Chirieac, Lucian R. ^{[8
]}

D'Amico, Thomas A. ^{[9
]}

Demmy, Todd L. ^{[7
]}

Dilling, Thomas J. ^{[10
]}

Dobelbower, M. Chris ^{[11
]}

Govindan, Ramaswamy ^{[12
,13
]}

Grannis, Frederic W., Jr. ^{[14
]}

Horn, Leora ^{[15
]}

Jahan, Thierry M. ^{[16
]}

Komaki, Ritsuko ^{[17
]}

Krug, Lee M. ^{[18
]}

Lackner, Rudy P. ^{[19
]}

Lanuti, Michael ^{[20
]}

Lilenbaum, Rogerio ^{[21
]}

Lin, Jules ^{[22
]}

Loo, Billy W., Jr. ^{[23
]}

Martins, Renato ^{[24
]}

Otterson, Gregory A. ^{[25
,26
]}

Patel, Jyoti D. ^{[27
]}

Pisters, Katherine M. ^{[17
]}

Reckamp, Karen ^{[14
]}

Riely, Gregory J. ^{[18
]}

Rohren, Eric ^{[17
]}

Schild, Steven E. ^{[28
]}

Shapiro, Theresa A. ^{[1
]}

Swanson, Scott J. ^{[8
]}

Tauer, Kurt ^{[29
]}

Yang, Stephen C. ^{[1
]}

Gregory, Kristina ^{[30
]}

Hughes, Miranda

机构：

[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA

[2] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[4] UC San Diego Moores Canc Ctr, San Diego, CA USA

[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[6] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[9] Duke Canc Inst, Durham, NC 27705 USA

[10] Moffit Canc Ctr, Tampa, FL 33612 USA

[11] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[12] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[13] Washington Univ, Sch Med, St Louis, MO 63130 USA

[14] City Hope Comprehens Canc Ctr, Duarte, CA USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[19] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[20] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[21] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[22] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[23] Stanford Canc Inst, Palo Alto, CA USA

[24] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[25] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[26] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA

[27] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[28] Mayo Clin, Ctr Canc, Rochester, MN USA

[29] Univ Tennessee, St Jude Childrens Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA

[30] Natl Comprehens Canc Network, Ft Washington, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2015年 / 13卷 / 05期

关键词：

GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; ESMO CONSENSUS CONFERENCE; ALK GENE REARRANGEMENT; ACQUIRED-RESISTANCE; EGFR MUTATION; CLINICOPATHOLOGICAL FEATURES; TUMOR SPECIMENS; OPEN-LABEL; CRIZOTINIB;

D O I：

10.6004/jnccn.2015.0071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

引用

页码：515 / 524

页数：10

共 80 条

[1] Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening Trial [J].

Aberle, Denise R. ;

Abtin, Fereidoun ;

Brown, Kathleen .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1002-1008

[2] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].

Aberle, Denise R. ;

Adams, Amanda M. ;

Berg, Christine D. ;

Black, William C. ;

Clapp, Jonathan D. ;

Fagerstrom, Richard M. ;

Gareen, Ilana F. ;

Gatsonis, Constantine ;

Marcus, Pamela M. ;

Sicks, JoRean D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409

[3] ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers [J].

Ali, Greta ;

Proietti, Agnese ;

Pelliccioni, Serena ;

Niccoli, Cristina ;

Lupi, Cristiana ;

Sensi, Elisa ;

Giannini, Riccardo ;

Borrelli, Nicla ;

Menghi, Maura ;

Chella, Antonio ;

Ribechini, Alessandro ;

Cappuzzo, Federico ;

Melfi, Franca ;

Lucchi, Marco ;

Mussi, Alfredo ;

Fontanini, Gabriella .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (11) :1449-1458

[4]

[Anonymous], 2014, SEER CANC STAT REV 1

[5] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[6] The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers [J].

Atherly, A. J. ;

Camidge, D. R. .

BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1100-1106

[7] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[8] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].

Besse, B. ;

Adjei, A. ;

Baas, P. ;

Meldgaard, P. ;

Nicolson, M. ;

Paz-Ares, L. ;

Reck, M. ;

Smit, E. F. ;

Syrigos, K. ;

Stahel, R. ;

Felip, E. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484

[9] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[10] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].

Camidge, D. Ross ;

Kono, Scott A. ;

Flacco, Antonella ;

Tan, Aik-Choon ;

Doebele, Robert C. ;

Zhou, Qing ;

Crino, Lucio ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590

← 1 2 3 4 5 6 7 8 →